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a b s t r a c t
The lower detection limit for 2 distinct crystalline phases by 1H magic-angle spinning (MAS) solid-state
nuclear magnetic resonance (NMR) is investigated for a minority amount of cimetidine (anhydrous
polymorph A) in a physical mixture with the anhydrous HCl salt of cimetidine. Speciﬁcally,
2-dimensional 1H double-quantum (DQ) MAS NMR spectra of polymorph A and the anhydrous HCl salt
constitute ﬁngerprints for the presence of each of these solid forms. For solid-state NMR data recorded at
a 1H Larmor frequency of 850 MHz and a MAS frequency of 30 kHz on ~10 mg of sample, it is shown that,
by following the pair of cross-peaks at a 1H DQ frequency of 7.4 þ 11.6 ¼ 19.0 ppm that are unique to
polymorph A, the level of detection for polymorph A in a physical mixture with the anhydrous HCl salt is
a concentration of 1% w/w.
© 2017 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Salt formation is the most general and effective method for
improving the aqueous solubility and dissolution rate of acidic and
basic drugs. Currently nearly half of all active pharmaceutical in-
gredients (APIs) used in medication are in salt forms.1 However,
during various processing steps such as milling, compression,
drying, and granulation, a salt can become unstable chemically and
physically, such that it may transform to its free acid/base form or
into other polymorphs or solvates. Many of the commonly used
excipients in tablet formulations are acidic or basic and can, thus,
change the local pH of a system. This can affect the stability of the
salt and cause the transformation of the salt to the corresponding
free acid/base form. The solid-state transformation from a salt to a
free formwill alter key properties of the API, such as solubility and
dissolution behavior, leading to undesired changes in the
bioavailability of the API.2 In order to monitor the quality of
pharmaceuticals, an effective and highly sensitive quantitation
method is required.
A variety of techniques have been used to characterize the
physicochemical properties of pharmaceuticals,3 including powder
X-ray diffraction (PXRD), differential scanning calorimetry (DSC),
and vibrational spectroscopies, notably IR and Raman. Although
PXRD is considered the deﬁnitive test for the identiﬁcation of a
speciﬁc solid-state form, the effectiveness of PXRD for quantitative
analysis of mixtures of solid phases can be diminished when the
effects of preferred orientation are signiﬁcant4; however, if the
crystal structures of all the solid forms present in the mixture are
known, then quantitative analysis can be carried out by Rietveld
reﬁnement in which the effects of preferred orientation are taken
rigorously into consideration. For example, Li et al.5 have shown
that the error associated with distinguishing polymorphs I and II of
sulfamerazine by DSC or PXRD was ±3%, which is superior to that
achieved by Raman spectroscopy. Siddiqui et al.6 have also used
PXRD (and solid-state nuclear magnetic resonance [NMR]) to
quantify the amount of crystalline tacrolimus solid dispersions,7
whereas Macfhionnghaile et al.8 have investigated the effect of
ball-milling and cryomilling on sulfamerazine using PXRD, IR, and
near-IR spectroscopy. Using terahertz (THz) spectroscopy,9
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Strachan et al.10 have shown that the concentration of carbamaz-
epine form III in a physical mixture with form I can be detected
down to a concentration of 1.5%. Moreover, Hisazumi et al.11 have
used THz spectroscopy to distinguish between anhydrous and hy-
drate forms of theophylline with an error of 3% in a pharmaceutical
formulation. Recently, Thakral et al.12 have used PXRD to follow salt
disproportionation, inwhich the PXRD data were measured using a
2-dimensional area detectordusing this technique, conventional 1-
dimensional PXRD patterns that are free from the effects of
preferred orientation can be obtained by appropriate integration of
the 2-dimensional data.
Solid-state NMR spectroscopy is an important method for phar-
maceutical analysis.13-17 Although the workhorse method is 13C
cross-polarization (CP) magic-angle spinning (MAS), the potential of
applying 1H fast MAS NMR is increasingly recognized for solid-state
analysis.18-48 In particular, the 1H double-quantum (DQ) solid-state
NMR experiment is a powerful probe of dipolar-coupled protons,
with DQ peaks observed for close (typically less than 3.5 Å) through-
space H$$$H proximities.49-51 Thus, a 2-dimensional 1HDQ spectrum
represents a “ﬁngerprint” for a speciﬁc 3-dimensional packing
arrangement adopted by an organic molecule, emphasizing the
advantage over 1-dimensional 1H or 13C NMR spectra of spreading
out into 2 dimensions. In this way, by using a high-resolution 1H DQ
combined rotation and multiple-pulse spectroscopy (CRAMPS)
approach,52 it has been shown how the presence of only the anhy-
drous form and not a hydrate form of an API in tablet formulation
can be established.19 However, due to the spectral noise associated
with the application of 1H homonuclear decoupling in the CRAMPS
approach, it is only possible to conclude that the hydrate form is
absent within a detection limit of ~5% for the spectra presented in
the study by Grifﬁn et al.19 An alternative approach is to use a
combination of fast MAS and high magnetic ﬁeld to give 1H DQMAS
spectra, where the resolution, although not as good as with the 1H
DQ CRAMPS method,51 is sufﬁcient to resolve distinct spectral fea-
tures. For the speciﬁc case of the anhydrous HCl salt of cimetidine
(the crystal structure of which has been determined recently53 by a
combined PXRD and NMR crystallography strategy) and the free
form of cimetidine (anhydrous polymorph A), this article in-
vestigates the lower limit of detection of a minority solid-state form
of an API, present in a physical mixture with another crystalline
phase of the same API, using 1H DQ MAS NMR spectroscopy.
Experimental Section
Cimetidine and cimetidine hydrochloride were purchased from
Sigma-Aldrich and used without further puriﬁcation. The identiﬁ-
cation of the speciﬁc solid-state form was conﬁrmed by PXRD as
shown in the studies by Tatton et al.33 and Watts et al.53 Samples
containing 10%, 5%, 1%, and 0.5% w/w polymorph A/anhydrous HCl
salt were prepared by physically mixing appropriately weighed
quantities of the 2 pure solid phases.
Solid-state NMR experiments were performed on a Bruker
Avance III spectrometer operating at a 1H Larmor frequency of 850.2
MHz (B0 ¼ 20.0 T) using a Bruker triple-resonance probe, operating
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Figure 1. 1H (850 MHz) DQ MAS (30 kHz) spectra of (a) the anhydrous HCl salt of
cimetidine, (b) polymorph A of cimetidine, and (c) a 10% w/w physical mixture of
polymorph A and the anhydrous HCl salt. An assignment of the 1H chemical shifts is
presented in Table 1, while Tables 2 and 3 list the expected 1H DQ peaks based on
H$$$H proximities extracted from the geometry-optimized (CASTEP) crystal structures.
The thick horizontal lines in (a) and (b) denote the pair of 1H DQ peaks corresponding
to the intramolecular proximity of the imidazole H2 (CH) and H3 (NH) protons, noting
that for the anhydrous HCl salt this overlaps with the pair of 1H DQ peaks corre-
sponding to the intramolecular proximity of the imidazole H2 (CH) and H1 (NHþ)
protons. The base contour levels are at (a) 5.4%, (b) 11%, and (c) 2.6% with respect to the
maximum peak height. (Note that a conference abstract has presented the spectra in
this ﬁgure in a different format.72)
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in double-resonance mode, supporting rotors of 2.5 mm outer
diameter (corresponding to ~10 mg of sample). AnMAS frequency of
30 kHz was used. The pulse sequence and coherence transfer
pathway diagram for the 1H DQ MAS49 experiment using back-to-
back recoupling54,55 are shown in Figure 7 of the review by Brown
and Spiess.56A 16-step phase cyclewas used to selectDp¼ ±2 on the
DQ excitation block and Dp ¼ 1 on the ﬁnal 90 pulse, where p is
the coherence order. The 1H 90 pulse duration was 2.5 ms. In all
experiments, 160 t1 FIDs were recorded with a rotor-synchronized t1
increment of 33.3 ms using the States time-proportional phase
incrementation method to achieve sign discrimination in F1. For the
anhydrous HCl salt of cimetidine and polymorph A of cimetidine, 16
transients were co-added with a recycle delay of 3 s. For the physical
mixtures of polymorph A and the anhydrous HCl salt, a recycle delay
of 9 s was used and 16 (10% and 5%w/wmixture samples), 48 (1% w/
w mixture sample), and 112 (0.5% w/w mixture sample) transients
were co-added. The experimental times were thus 2 h (anhydrous
cimetidine hydrochloride and cimetidine polymorph A), 6 h (10%
and 5% w/w mixture samples), 19 h (1% w/w mixture sample), and
44 h (0.5% w/w mixture sample).
1H chemical shifts are referencedwith respect to neat TMS using
adamantane as a secondary reference (1.85 ppm for 1H).57 Experi-
mental 1H chemical shifts are stated to an accuracy of ±0.1 ppm.
Results and Discussion
1H DQ MAS Solid-State NMR Spectra
In previous studies, 1-dimensional 13C CP MAS NMR spectra, as
well as the results of various heteronuclear dipolar experiments,
have been presented for a free form of cimetidine (polymorph
A),58,59whereas a 13C CPMAS spectrum of the anhydrous HCl salt of
cimetidine as well as a gauge-including projector-augmented wave
(GIPAW) calculation60,61 of the NMR parameters (for the reported
crystal structure following geometry optimization) have been
presented recently.53 Tatton et al.33 have also presented 15N-1H
spectral-editing and 14N-1H and 15N-1H correlation spectra for
polymorph A of cimetidine, together with GIPAW calculations of
the chemical shielding and electric ﬁeld gradient tensors for the
reported crystal structure62 following geometry optimization. Note
that distances stated in this paper are from the geometry-
optimized crystal structures on which these GIPAW calculations
were carried out (available as Supporting Information in studies by
Tatton et al.33 and Watts et al.53).
Figures 1a and 1b present 1H DQ MAS NMR spectra of (a) the
anhydrous HCl salt of cimetidine and (b) polymorph A of cimeti-
dine, recorded at a 1H Larmor frequency of 850 MHz and an MAS
frequency of 30 kHz. Because 1H linewidths for the strongly
dipolar-coupled network of protons in organic solids decrease with
increasing MAS frequency,63,64 narrower 1H linewidths would be
observed using the higher MAS frequencies of >60 kHz that can be
achieved with rotors of smaller outer diameter (1.3 mm and less).
However, the improved resolution would come at the cost of lower
sensitivity associated with the considerably reduced sample vol-
ume (corresponding to sample mass ~1 mg or less). Enhanced
resolution could also be achieved using the 1H DQ CRAMPS
approach (e.g., see Fig. 3 of the review by Brown51) but, as noted in
the Introduction, the disadvantage of using 1H homonuclear
decoupling is the observation of additional “noise” in the spectra
which limits the lower detection of the minority phase to ~5%. For
these reasons, it was decided that 30-kHz MAS at a 1H Larmor
frequency of 850MHz provided the best compromise of sufﬁciently
high-resolution and optimum sensitivity for 1H DQ MAS NMR
spectroscopy of the anhydrous HCl salt and polymorph A of cime-
tidinedsee the spectra presented in Figures 1a and 1b.
The 1H DQ MAS NMR spectra presented in Figure 1 were
recorded using 1 rotor period of back-to-back recoupling.54,55 Such
1H DQ MAS NMR spectra probe DQ coherences between pairs of
through-space dipolar coupled protons corresponding to a close
(typically less than 3.5 Å) H$$$H distance,49,51 with DQ peaks
Table 2
H$$$H Proximitiesa (<3.5 Å) and Corresponding 1H DQ Shifts (See Fig. 1a) for the NH
and Imidazole CH Protons in the Anhydrous HCl Salt of Cimetidine
Atom Descriptor Atom Label dSQ/ppm dDQ/ppm Distance/Å
H1 (NHþ) (15.0 ppm) H2 (CH) 9.4 24.4 2.57
H6b (CH2) 3.6 18.6 2.70
H7c (CH3) 2.6 17.6 2.82
H16c (CH3) 2.6 17.6 2.94
H16a (CH3) 2.6 17.6 3.18
H3 (NH) 15.0 30.0 3.43
H7a (CH3) 2.6 17.6 3.49
H2 (CH) (9.4 ppm) H1 (NHþ) 15.0 24.4 2.57
H3 (CH) 15.0 24.4 2.57
H7c (CH3) 2.6 12.0 2.69
H6b (CH2) 3.6 13.0 2.82
H6a (CH2) 3.6 13.0 3.06
H6a (CH2) 3.6 13.0 3.13
H16b (CH3) 2.6 12.0 3.39
H3 (NH) (15.0 ppm) H2 (CH) 9.4 24.4 2.57
H6b (CH2) 3.6 18.6 2.71
H7c (CH3) 2.6 17.6 2.73
H6a (CH2) 3.6 18.6 2.95
H7b (CH3) 2.6 17.6 3.04
H9a (CH2) 2.6 17.6 3.15
H16c (CH3) 2.6 17.6 3.35
H6a (CH2) 3.6 18.6 3.39
H1 (NHþ) 15.0 30.0 3.43
H10 (NH) (5.0 ppm) H9a (CH2) 2.6 7.6 2.29
H9b (CH2) 2.6 7.6 2.94
H8b (CH2) 2.6 7.6 2.98
H7b (CH3) 2.6 7.6 3.03
H16c (CH3) 2.6 7.6 3.31
H8a (CH2) 2.6 7.6 3.33
H7a (CH3) 2.6 7.6 3.36
H15 (NH) (6.7 ppm) H9b (CH2) 2.6 9.3 2.17
H16a (CH3) 2.6 9.3 2.24
H8a (CH2) 2.6 9.3 2.26
H16b (CH3) 2.6 9.3 2.72
H16c (CH3) 2.6 9.3 2.93
H8a (CH2) 2.6 9.3 2.94
Intermolecular proximities are in italics.
a Distances are stated for the geometry-optimized (CASTEP) crystal structure.
Table 1
Experimentala and GIPAW-Calculatedb 1H Chemical Shifts (in ppm) for the
Anhydrous HCl Salt and Polymorph A of Cimetidine
Atom
Label
Atom
Descriptor
Anhydrous HCl Salt Polymorph A
Experimental Calculated Experimental Calculated
H1 NHþ 15.0 15.5 e e
H2 CH 9.4 9.2 7.4 7.1
H3 NH 15.0 15.3 11.6 11.9
H6a CH2 3.6 4.3 4.0 3.4
H6b CH2 3.6 3.8 4.0 3.0
H7a-cc CH3 2.6 2.9 2.0 1.3
H8a CH2 2.6 2.4 3.0 1.3
H8b CH2 2.6 0.7 3.0 0.2
H9a CH2 2.6 2.8 3.0 2.4
H9b CH2 2.6 1.9 3.0 2.7
H10 NH 5.0 4.6 8.2 8.2
H15 NH 6.7 6.9 9.7 9.6
H16a-cc CH3 2.6 1.4 2.0 1.5
a It is not possible to distinguish some separate CH2 and CH3
1H resonances in the
experimental spectra.
b Calculated isotropic chemical shifts are obtained from the calculated absolute
shielding as dcalciso ¼ sref  scal , where sref ¼ 30.0 ppm.
c For CH3 groups, the stated value of the calculated isotropic chemical shift is the
average for the 3 protons.
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observed at the sum of the 2 single-quantum (SQ) frequencies.
Table 1 presents an assignment of the experimentally observed 1H
chemical shifts for polymorph A and the anhydrous HCl salt of
cimetidine based on GIPAW calculations (as reported previ-
ously).33,53 The signiﬁcant change in the 1H chemical shift of H3
reﬂects the change from an NH$$$N intermolecular hydrogen bond
with N12 as the acceptor in polymorph A (involving uncharged
donor and acceptor groups) to an NHþ$$$Cl intermolecular
hydrogen bond (involving charged donor and acceptor groups) in
the anhydrous HCl salt.
Tables 2 and 3 list H$$$H proximities under 3.5 Å for the NH and
imidazole CH protons and the corresponding 1H DQ shifts for the
anhydrous HCl salt and polymorph A of cimetidine, respectively.
For the anhydrous HCl salt, the NHþ (H1) and NH (H3) imidazole 1H
chemical shifts overlap (at 15.0 ppm, see Table 1). Thus, in the 1H
DQ MAS spectrum in Figure 1a, the pair of 1H DQ peaks at dDQ ¼
15.0 þ 9.4 ¼ 24.4 ppm corresponds to an intramolecular proximity
of 2.57 Å for the imidazole CH (H2) with both the NHþ (H1) and NH
(H3) protonsdsee Table 2. We also note the very weak diagonal
peak at dDQ ¼ 15.0 þ 15.0 ¼ 30.0 ppm in Figure 1a that corresponds
to a 3.43 Å intermolecular proximity of the NHþ (H1) and NH (H3)
protons (also see Table 2). As described in the study by Bradley
et al.,65 to a ﬁrst approximation, the relative intensity of distinct 1H
DQ peaks at the same 1H single-quantum chemical shift is pro-
portional to the ratio of the square of the dipolar coupling constants
and hence is inversely proportional to ratio of H$$$H distances to
the sixth powerdnote that (3.43/2.57)6 ¼ 5.7. Other cross-peaks
observed for the NH groups in the 1H DQ MAS spectra in
Figures 1a and 1b are due to intra- and intermolecular proximities
to CH2 and CH3 protons (see Tables 2 and 3).
This study is focused on the pair of 1H DQ peaks due to the
intramolecular proximity of 2.57 and 2.55 Å for the imidazole H2
(CH) and H3 (NH) protons, whereby dDQ ¼ 15.0þ 9.4¼ 24.4 ppm in
Figure 1a for the anhydrous HCl salt and dDQ¼ 11.6þ 7.4¼19.0 ppm
in Figure 1b for polymorph A. The evident change in the positions of
the pair of 1H DQ peaks due to the intramolecular proximity of the
imidazole H2 (CH) and H3 (NH) protons between the anhydrous
HCl salt and polymorph A constitutes a “ﬁngerprint” that is a
diagnostic for the presence of either or both of the distinct solid-
state forms.
Probing the Level of Detection of a Minority Phase in a Physical
Mixture of 2 Distinct Crystalline Phases
To determine the level of detection by 1H DQ MAS NMR of
polymorph A of cimetidine in a physical mixture with the anhy-
drous HCl salt of cimetidine, spectra were recorded for samples
comprising 10%, 5%, 1%, and 0.5% w/w mixtures of polymorph A/
anhydrous HCl salt. Speciﬁcally, Figure 1c presents a 1H DQ MAS
NMR spectrum of the 10% w/w mixture (note the lower base con-
tour in Fig. 1c as compared to Figs. 1a and 1b). It is evident that a
weak pair of 1H DQ peaks at dDQ ¼ 11.6 þ 7.4 ¼ 19.0 ppm due to
Table 3
H$$$H Proximitiesa (<3.5 Å) and Corresponding 1H DQ Shifts (See Fig. 1b) for the NH
and Imidazole CH Protons in the Geometry-Optimized (CASTEP) Crystal Structure of
Polymorph A of Cimetidine
Atom Descriptor Atom Label dSQ/ppm dDQ/ppm Distance/Å
H2 (CH) (7.4 ppm) H3 (NH) 11.6 19.0 2.55
H16a (CH3) 2.0 9.4 2.59
H7c (CH3) 2.0 9.4 2.87
H7a (CH3) 2.0 9.4 2.93
H15 (NH) 9.7 17.1 3.00
H7b (CH3) 2.0 9.4 3.05
H6b (CH2) 4.0 11.4 3.27
H16c (CH3) 2.0 9.4 3.50
H3 (NH) (11.6 ppm) H16b (CH3) 2.0 13.6 2.52
H2 (CH) 7.4 19.0 2.55
H7a (CH3) 2.0 13.6 2.59
H7b (CH3) 2.0 13.6 2.81
H7c (CH3) 2.0 13.6 3.09
H7b (CH3) 2.0 13.6 3.10
H16a (CH3) 2.0 13.6 3.13
H10 (NH) (8.2 ppm) H9a (CH2) 3.0 11.2 2.27
H16c (CH3) 2.0 10.2 2.71
H9b (CH2) 3.0 11.2 2.93
H8b (CH2) 3.0 11.2 2.99
H8a (CH2) 3.0 11.2 3.42
H15 (NH) (9.7 ppm) H9b (CH2) 3.0 12.7 2.20
H16a (CH3) 2.0 11.7 2.22
H8a (CH2) 3.0 12.7 2.29
H16c (CH3) 2.0 11.7 2.81
H16b (CH3) 2.0 11.7 2.90
H2 (CH) 7.4 16.1 3.00
H6a (CH2) 4.0 13.7 3.19
H7b (CH3) 2.0 11.7 3.22
H7c (CH3) 2.0 11.7 3.40
Intermolecular proximities are in italics.
a Distances are stated for the geometry-optimized (CASTEP) crystal structure.
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polymorph A is observed in addition to the stronger 1H DQ peaks at
dDQ ¼ 15.0 þ 9.4 ¼ 24.4 ppm due to the anhydrous HCl salt. Thus, it
is necessary to focus on the peaks observed at a 1H DQ frequency of
19.0 ppm, and Figure 2 presents slices at this DQ frequency for (a)
the anhydrous HCl salt of cimetidine, (b) polymorph A of cimeti-
dine, and (c-f) physical mixtures of polymorph A with the anhy-
drous HCl salt with (c) 10%, (d) 5%, (e) 1%, and (f) 0.5% w/w of
polymorph A. For the anhydrous HCl salt, we note that there are 1H
DQ peaks at dDQ ¼ 15.0 þ 4.0 ¼ 19.0 ppm due to proximity with
aliphatic protonsdsee Figs. 1a and 2a. The spreading into 2 di-
mensions allows these to be distinguished from the 1H DQ peaks at
dDQ ¼ 11.6 þ 7.4 ¼ 19.0 ppm, characteristic of polymorph A.
Following the dashed lines through the peaks at dSQ ¼ 11.6 and 7.4
ppm, it is observed that the 1H DQ peaks due to polymorph A are
still evident above the noise level down to the 1% w/w mixture in
Figure 2e. This conclusion is conﬁrmed by the signal-to-noise
analysis presented in Table 4 for the peaks at a 1H DQ frequency
of 19.0 ppm for the H2 and H3 1H SQ resonances at 11.6 and 7.4
ppm. Following the guidance of the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use, Validation of Analytical Proced-
ures: Text and Methodology Q2(R1), section 6.2 states that “A
signal-to-noise ratio between 3 or 2:1 is generally considered
acceptable for estimating the detection limit.”66 As such, the data in
Table 4 establish 1% w/w as the level of detection using 1H DQMAS
NMR at 30-kHz MAS and a 1H Larmor frequency of 850 MHz for 2
crystalline phases of cimetidine.
Conclusions
Two distinct crystalline phases of cimetidine, polymorph A and
the anhydrous HCl salt, are clearly distinguished using 1H DQ MAS
solid-state NMR spectroscopy by focusing on the pair of 1H DQ
peaks due to the intramolecular proximity (2.55 or 2.57 Å) of the
neighboring H2 (CH) and H3 (NH) protons of the imidazole ring.
Protonation at the N1 site in the anhydrous HCl salt as well as the
fact that the 2 distinct solid-state forms have different intermo-
lecular hydrogen-bonding arrangements leads to 1H DQ peaks at
dDQ¼ 15.0þ 9.4¼ 24.4 ppm for the anhydrous HCl salt and at dDQ¼
11.6 þ 7.4 ¼ 19.0 ppm for polymorph A. By spreading out the peaks
into 2 dimensions, the observation of 1H DQ peaks at dDQ ¼ 11.6 þ
7.4 ¼ 19.0 ppm is an unambiguous indicator of the presence of
polymorph A. Using this “ﬁngerprint”, solid-state NMR experi-
ments carried out at a 1H Larmor frequency of 850MHz and anMAS
frequency of 30 kHz have shown that polymorph A can be detected
and quantiﬁed in a physical mixture with the anhydrous HCl salt
down to a concentration of 1% w/w. Considering literature reports
(see Introduction), this level of detection matches and in some
cases improves upon that reported for other analytical techniques,
for example, PXRD, DSC, Raman spectroscopy, and THz spectros-
copy. In particular, we emphasize that distinguishing between 2
crystalline phases represents a different challenge to the identiﬁ-
cation of aminority amount of a crystalline phase in the presence of
an amorphous phase.
We note that employing 1HDQMAS represents a complementary
approach to solid-state NMR of other nuclei, notably 13C and 19F.67,68
Moreover, it has recently been shown that the sensitivity of solid-
state NMR spectroscopy of moderately sized organic molecules can
be signiﬁcantly enhanced (e.g., by 5 times for paracetamol) by
employing dynamic nuclear polarization, such that 13C refocused
INADEQUATE spectra can be recorded at natural isotopic abundance
in 16 h for sulfathiazole (which has a long T1 relaxation time,
necessitating a recycle delay of 30 s)69 and 15N-1H correlation spectra
can be obtained also at natural isotopic abundance for a pharma-
ceutical formulation.70 With the recent development of new dy-
namic nuclear polarization 1.3-mm MAS probe technology that
allows faster MAS,71 this approach seems promising for progressing
to even lower levels of detection of minority solid-state forms by 1H
DQ MAS. This approach would also reduce the required experi-
mental time (in this work, 19 h for the 2-dimensional spectrum of
the 1% w/w sample), noting that experimental times are typically
shorter for other techniques such as PXRD, Raman, and IR. Finally, as
shown in our earlier work employing a 1H DQ CRAMPS approach,19
we note that the 1H DQ solid-state NMR method presented here is
readily applicable to tablet formulations with the shift of 1H DQ
peaks due to hydrogen-bonded protons to high ppmhelping to avoid
overlap with 1H resonances of the excipients.
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